Holy Name is 1st in U.S. to enroll patient in PICCOLO study targeting platinum-sensitive ovarian cancer

Holy Name Medical Center is the first site in the nation to open ImmunoGen’s PICCOLO study, which targets platinum-sensitive ovarian cancer.

Under the supervision of Dr. Sharyn Lewin, chief of gynecologic oncology, the patient was enrolled in the single-arm clinical trial at Holy Name’s Patricia Lynch Cancer Center in Teaneck in November.

The PICCOLO study is among a growing portfolio of clinical trials offered through Holy Name’s Institute for Clinical Research. Right now, there are over a dozen investigational studies — and several more in the pipeline — that specifically involve treatments for gynecologic cancers.

“Holy Name is proud to provide access to this important clinical trial to our patient population and women around the tri-state area. Participating in national trials puts Holy Name in a league with some of the most respected research and medical centers in the country,” Lewin said. “Through our continued participation in clinical trials like PICCOLO, we’re contributing to studies designed to improve outcomes, including quality of life and progression-free survival for the women who trust us with their care.”

The study evaluates the safety and efficacy of mirvetuximab soravtansine as a single agent in patients with folate receptor alpha high, recurrent platinum-sensitive ovarian cancer.

ImmunoGen is a leader in the expanding field of antibody-drug conjugates for the treatment of cancer. ADCs are targeted therapies designed to kill cancer cells and spare healthy cells. To date, mirvetuximab has generated promising data in patients with platinum-resistant ovarian cancer; this study in platinum-sensitive ovarian cancer is designed to address another patient population with high unmet need.